August 31st, 2026
Here, researchers report on their investigation of gene therapy to introduce a bacterial enzyme, lipoic acid protein ligase A (LplA), into mammals in order to improve mitochondrial metabolism. LplA undertakes lipoylation of proteins, attaching lipoic acid to the protein, and does so somewhat more efficiently than the analogous enzymes in mammals. Lipoylation is known to be involved in the regulation of metabolism, and is largely researched in the context of conditions exhibiting lipoylation deficiency. Here, however, the focus is on enhancement of metabolism in healthy individuals over the course of aging. This is interesting work, but at the present time it would be very hard to convince investors to fund and regulators to approve the introduction of a bacterial protein into humans as a basis for therapy; there is a strong assumption that a negative immune reaction would result, and a consequently high bar set for proof that it doesn't.
As primary energy producers, mitochondria generate adenosine 5′-triphosphate (ATP) through efficient oxidative phosphorylation, but this process inevitably produces reactive oxygen species (ROS), which act as crucial signaling mediators at physiological levels yet become drivers of cellular aging and functional decline when accumulated excessively. Thus, an essential challenge involves maintaining an optimal balance between energy production and ROS management to achieve truly efficient and clean energy metabolism. This biochemical context raises the core question of whether interventions can be developed that enhance energy metabolism while simultaneously minimizing oxidative damage, thereby combining the benefits of both vitality and longevity.
